Keros Therapeutics Stock Performance
| KROS Stock | USD 18.86 0.40 2.08% |
On a scale of 0 to 100, Keros Therapeutics holds a performance score of 9. The company secures a Beta (Market Risk) of 0.54, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Keros Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Keros Therapeutics is expected to be smaller as well. Please check Keros Therapeutics' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Keros Therapeutics' current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Keros Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Keros Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.08) | Five Day Return (2.68) | Year To Date Return 1.73 | Ten Year Return (6.08) | All Time Return (6.08) |
1 | Acquisition by Nussbaum Ran of 10500 shares of Keros Therapeutics at 14.82 subject to Rule 16b-3 | 11/07/2025 |
2 | How Much Upside is Left in Keros Therapeutics Wall Street Analysts Think 34.24 | 11/26/2025 |
3 | Stocks to watch Keros Therapeutics sees relative strength rating rise to 82 - MSN | 12/05/2025 |
4 | What Makes Keros Therapeutics, Inc. a Strong Momentum Stock Buy Now | 12/12/2025 |
5 | Keros Therapeutics Shares Down 3.7 percent Whats Next | 12/18/2025 |
6 | Heres Why Keros Therapeutics Could be Great Choice for a Bottom Fisher | 12/22/2025 |
7 | Short Interest in Keros Therapeutics, Inc. Decreases By 16.6 | 12/31/2025 |
8 | Acquisition by Jasbir Seehra of 62500 shares of Keros Therapeutics at 63.61 subject to Rule 16b-3 | 01/07/2026 |
9 | BEAM Outlines Key Strategic Pipeline Goals for 2026, Stock Rises - Zacks Investment Research | 01/13/2026 |
10 | Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia | 01/16/2026 |
| Begin Period Cash Flow | 332.4 M | |
| Total Cashflows From Investing Activities | -1.9 M |
Keros Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,541 in Keros Therapeutics on October 21, 2025 and sell it today you would earn a total of 345.00 from holding Keros Therapeutics or generate 22.39% return on investment over 90 days. Keros Therapeutics is currently generating 0.3664% in daily expected returns and assumes 3.0558% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Keros, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Keros Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Keros Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Keros Therapeutics, and traders can use it to determine the average amount a Keros Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1199
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KROS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Keros Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Keros Therapeutics by adding it to a well-diversified portfolio.
Keros Therapeutics Fundamentals Growth
Keros Stock prices reflect investors' perceptions of the future prospects and financial health of Keros Therapeutics, and Keros Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Keros Stock performance.
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.044 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | (1.08) % | ||||
| Current Valuation | (101.45 M) | ||||
| Shares Outstanding | 30.47 M | ||||
| Price To Book | 0.82 X | ||||
| Price To Sales | 2.33 X | ||||
| Revenue | 3.55 M | ||||
| Gross Profit | 91.76 M | ||||
| EBITDA | (185.82 M) | ||||
| Net Income | (187.35 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 18.86 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 17.32 X | ||||
| Cash Flow From Operations | (160.87 M) | ||||
| Earnings Per Share | 1.56 X | ||||
| Market Capitalization | 574.59 M | ||||
| Total Asset | 615.89 M | ||||
| Retained Earnings | (568.78 M) | ||||
| Working Capital | 561.44 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
About Keros Therapeutics Performance
Assessing Keros Therapeutics' fundamental ratios provides investors with valuable insights into Keros Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Keros Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.30) | (0.31) |
Things to note about Keros Therapeutics performance evaluation
Checking the ongoing alerts about Keros Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Keros Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Keros Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 3.55 M. Net Loss for the year was (187.35 M) with profit before overhead, payroll, taxes, and interest of 91.76 M. | |
| Keros Therapeutics currently holds about 215.62 M in cash with (160.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.37. | |
| Keros Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia |
- Analyzing Keros Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Keros Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Keros Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Keros Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Keros Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Keros Therapeutics' stock. These opinions can provide insight into Keros Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.